S. Keating

The influence of HLA‐matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA

S. Keating, Théo de Witte, Stefan Suciu et al. · British Journal of Haematology · 1998 · 91 citations · Full text

Medicine, Hematology, Immunology +17

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial

S. Keating, Stefan Suciu, T. de Witte et al. · Leukemia · 2003 · 65 citations · Full text

Medicine, Oncology, Cell Therapy +15

Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.

S. Keating, Stefan Suciu, T.J.M. de Witte et al. · PubMed · 1996 · 59 citations

Medicine, Hematology, Oncology +15